Tempus AI is acquiring cancer-monitoring firm Personalis in a $1.5 billion stock deal Jul 21, 2026 · Cris Tolomia The deal, structured as an all-stock transaction, gives Tempus control of Personalis' NeXT Personal cancer detection test Read more »
.jpg?branch=production)
